LGND Ligand Corp: Enterprise Value to EBITDA Ratio
Ligand Pharmaceuticals (LGND) generates royalty revenue by integrating the Captisol system into the formulas of industry behemoths. Data from GURU.Markets is used for this EV/EBITDA enterprise value multiple chart, where the metric level stands at 94.12. The company is modernizing its centers to meet ESG standards by utilizing waste. However, a heavy reliance on external contractors forces management to regularly update its pool of manufacturing partners.
Comprehensive metric breakdowns and analytics for Ligand Pharmaceuticals Incorporated (LGND)
- market price and analyst price targets:
- company stock capitalization data:
- business book valuation details:
- debt obligations and liquidity statistics:
- financial results and valuation multiples details:
LGND - Net Profit|Expected Profit Ligand Pharmaceuticals|LGND - Price to Earnings Multiple|Forward P/E Multiple Ligand Pharma|LGND - Growth-Adjusted P/E Ratio|Enterprise Value to EBITDA Ratio Ligand Pharmaceuticals Incorporated|LGND - Income before deduction of interest, taxes and amortization|Earnings per share for the last twelve months Ligand|LGND - Earnings per one share for the last 12 months|Quarterly EPS earnings growth ligand.com|LGND - Earnings per share increase in current year|Earnings growth forecast for next year Ligand Pharmaceuticals
- company sales and revenue statistics:
Summary company analytics:ligand.com LGND
The EV/EBITDA multiple determines the business value relative to its operating profit before depreciation, taxes, and interest, allowing for an assessment of cash flow generation efficiency regardless of capital structure. By analyzing changes in the EV/EBITDA level of Ligand Pharmaceuticals (LGND), an investor can observe the asset's stability, as the pharmaceutical business's royalty model minimizes the impact of economic cycles and macro shocks on market value.
Analysis of competing companies
Haleon Group - Enterprise Value to EBITDA Ratio|Kenvue (KVUE) - Company Value to EBITDA|VRNA: Enterprise Value to EBITDA Ratio|Jyong Biotech - Enterprise Value to Operating Income Before Depreciation Ratio|AMRX: EV/EBITDA Multiple|Perrigo Company - Business Value to Operating Income Before Depreciation|ALVO (Alvotech S.A.) - EV/EBITDA Multiple|Company Value to EBITDA liquidia.com LQDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Galapagos (GLPG)|ANIP (ANI Pharmaceuticals, Inc.) - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Afrezza MNKD|EV/EBITDA Multiple Amphastar Corp AMPH|Pacira Corp - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation SPRY (ars-pharma.com)|TBPH: EV/EBITDA Multiple|Aquestive Therapeutics, Inc. (AQST) - EV/EBITDA Multiple|SCPH (scpharmaceuticals.com) - EV/EBITDA Multiple|TECX (tectonictx.com) - Enterprise Value to Operating Income Before Depreciation Ratio|Enterprise Value to EBITDA Ratio TNXP (Tonix Pharmaceuticals Holding Corp.)|EV/EBITDA Multiple SXT China (SXTC)|eupraxiapharma.com - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BHST|invizyne.com - EV/EBITDA Multiple|Business Value to Operating Income Before Depreciation ORMP (Oramed Pharmaceuticals Inc.)|ENTX: EV/EBITDA Multiple|MindWalk Holdings Inc. (HYFT) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ABVC BioPharma|Enterprise Value to Operating Income Before Depreciation CPIX (Cumberland Pharmaceuticals Inc.)|EV/EBITDA Multiple QNTM|Total Company Value to Operating Income Before Depreciation Ratio FibroGen Corporation|EV/EBITDA Multiple TELO (Telomir Pharmaceuticals Corp)|RANI (Rani Therapeutics Inc) - Company Value to Operating Income Before Depreciation Ratio|SNYR: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation RLYB (Rallybio)|LEXX: EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Pulmatrix, Inc.|PTHL (Pheton Holdings Ltd) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization APM|EV/EBITDA Multiple LYRA|EV/EBITDA Multiple Impact BioMedical, Inc. (IBO)|EV/EBITDA Multiple TNFA (TNF Pharmaceuticals)|Business Value to Operating Income Before Depreciation YCBD|PRFX - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|CYTO - EV/EBITDA Multiple|LIPO (Lipella Pharmaceuticals) - Enterprise Value to EBITDA Ratio|Company Value to Operating Income Before Depreciation Ratio OPTN (OptiNose)|PIRS (Pieris Pharma) - EV/EBITDA Multiple|Procaps Group Corp - Company Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple PTPI|qlsyy.net (QLI) - Enterprise Value to EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization ACELYRIN SLRN|TFFP (TFF Pharmaceuticals, Inc.) - Company Value to Operating Income Before Depreciation Ratio
